Overview
Our Transparency
We pursue the ethical and social commitment to improve corporate values continually for company members as well as various shareholders on the basis of its mission: “to become a total healthcare leader of health, medical, and wellness industries with customer satisfaction as the top priority.”
Message from
our CEO
We supply a top wide-range of prescription medicines for skin healthcare. As it pursues sustainable growth through co-prosperity and fulfills its social commitment, We have continued to practice its principle of ethical management since its foundation.
In recognition that the practice of ethical management is the very basis for a company’s sustainable growth, We have put forth every effort to establish the internal foundation for ethical management since April 2014 when the regulations on autonomous fair trade and to internalize its ethical management with the CP team newly established in 2016. In addition, We have implemented its anti-bribery policy since its establishment on July 01, 2018, in order to promote ethical management all together. It also focuses its company-wide capability on operating the anti-bribery management system.
As every interested one of the company including executives and employees and business partners of Dongkoo Bio&Pharma practices ethical management, we will spare no effort to grow together. We will also try its best to grow into a total healthcare leader in the global market.
The Compliance
code of conduct
-
For our patients
Each employee pays keen attention to patient’ voice with patient satisfaction and trust as the top priority.
The company recognizes customers’ health and life as the most important values and puts forth every effort to protect them. -
Our social contribution
Each employee contributes to the country’s advancement as it creates social wealth through sound corporate activity and improves the quality of the national life.
We respect various social values such as law, custom, culture, free competition, and environmental preservation and puts forth efforts for common development. -
Our commitment to prevent
corruptionWe require the highest standards of professional and ethical conduct from its employees, officers, corporate auditors and directors.
No employee, officer, corporate auditor or director will be permitted to achieve results through violations of laws or regulations or through unscrupulous dealings. -
In how we conduct our business
Each employee avoids an illegal act involving the exchange of consideration, such as money, with the purpose of influencing behavior.
We faithfully comply with regulations while handling duties regarding information protection, intellectual property right protection, prohibition of conflict of interest, etc. -
Our commitment for shareholders
and investorsWe secure soundness of business management to increase investment values and productivity and protects profits of shareholders and investors.
We provide required information in a timely manner, guarantees just rights of shareholders and investors, and avoids any act of damaging corporate values.
The Eight
compliance
principles
This Code aims to specify the code of conducts for executives and employees to prevent corruption and bribery in Dongkoo Bio&Pharma and to firmly establish the anti-bribery management system.
We prohibit bribery, including bribes and entertainment from stakeholders, and any corrupt practices.
Each employee complies with corporate policies and foreign anti-bribery laws including those below Korean and foreign abstain from being involved in acts of violation or suspicious of violation: Korean 「Criminal Act」, 「Monopoly Regulation and Fair Trade Act」, 「Improper Solicitation and Graft Act」, 「Pharmaceutical Affairs Act」, 「Aggravated Punishment, etc. of Specific Crimes」, and 「Act on Combating Bribery of Foreign Public Officials in International Business Transactions」, U.S. 「Foreign Corrupt Practices Act」, U.K. 「Bribery Act」, etc.
Each employee must not engage in any act that interferes or conflicts, or has the potential to interfere or conflict, with the interests of the Company.
We shall establish, operate, and continually improve an effective management system in order to prevent and minimize risks of corruption. In addition, executives and employees sign and fulfill the agreement of anti-bribery on a yearly basis.
Our compliance team have authorities and responsibilities to work independently related to corruption and bribery prevention and is obligated to provide and supervise advice and instructions to address issues related to the company’s anti-bribery management system.
Our company keeps strictly confidential identity information of corruption informants. The personal information must not tell, disclose or publicize and shall be protected from any disadvantages in terms of performance evaluation, personnel transfer, and financial issues. Informants’ contribution to the company is reflected in work performance.
When any employee violation against laws related to this policy and then takes no reasonable action, the company does not take the responsibility on behalf of the executive or employee and may take a disciplinary action in accord with the company's regulations.
1. This policy is effective from its establishment on July 01, 2018.
Compliance Program
About CP
The Compliance Program is to promote compliance with laws and guidelines related to fair competition in corporate economic activities and to establish, operate, and supervise its internal compliance system and code of conduct.
Accordingly, Dongkoo Bio&Parma Co., Ltd. stipulates and practices internal standards and procedures as the basis for work performance and decision-making in accordance with relevant laws for autonomous fair trade and fair competition regulations of Korea Pharmaceutical and Bio-Pharma Manufacturers Association.
CP Highlights
-
Monitoring system operation
Establishment and operation of the monitoring system to verify the compliance with the Pharmaceutical Affairs Act and CP regulations
-
Continued education and training
Classifying risks related to CP regulations on each job type, providing regular CP education/training programs, and evaluating education/training results
-
Operation of reward and punishment regulations
Reward and punishment on relevant individuals according to CP regulations
Historical CP
ABMS
About ABMS
The Anti-bribery management system (hereunder, referred to as “ABMS”) is to specify regulations, procedures, responsibilities, and authorities necessary to prevent various corruptions and to implement, maintain, review, and improve them constantly.
ABMS Highlights
-
Management leadership
Expressing the will of anti-corruption in and out of the company; providing sufficient and appropriate resources for the effective operation of the ABMS
-
Third party management
Transparency in the relation with major business parties; fulfilling the integrity agreement as part of each contract; providing a business partner with a clean report or an education program for transparency
-
Certification
Acquiring and maintaining official certificates of ABMS operation (ISO37001)
Historical ABMS
Equity
About Clean Bell
At Dongkoo Bio&Pharma, Equity means that every person deserves to be seen, heard, and cared for.
Informants’ valuable opinions are treated in a prompt, confidential, and fair manner at the CP department in order to protect the informant and other related individuals.
Protection of informants
- We treats as confidential information and strictly protect an informant’s identity (or information that implies the identity) and reports.
- An informant may report in an anonymous or unregistered manner.
- We protects informants from any type of discrimination, retaliation, or disadvantage. (However, an informant who also is involved in an act of violation is exempted. In this case, the informant is subject to proper extenuation and reasonable treatment.)
- Those who provide a statement or material in the process of fact checking about a report are also protected on the level of informants.
Acts to be
reported
- Acts of providing or asking money/goods, entertainments, treats from an interested one
- Acts of using the company’s asset in an illegal, unjust, or inappropriate way
- Acts of violating related laws such as Pharmaceutical Affairs Act, Anti-graft Act, and Fair Trade Act
- Acts of violating the anti-bribery policy
- Acts of harming the sound corporate culture (e.g.: sexual harassment, violent language, violence, abusing the power, negligence of duty, abuse of one’s authority, etc.)
- Acts of unfair equity participation in a partner company
- Other unethical acts against the company’s ethical management
- Proposals for institutional/work improvement
Reporting method
and procedure
- Essential information : contacts (e-mail, etc.) via which the results could be notified
- Considerations
- Please state details to be reported in 5W’s and 1H if possible.
- If there are aspects uncertain, the investigation may not be able to be performed.
- If you attach related documents, the report may be handled in a faster and more effective manner.
- Any false accusation or baseless slanders against others are not supposed to be reported.
-
Submit
- Enter the personal email to communicate
- Description in detail (What, Who, Where, When, Why and How)
- Attaching documents if possible
-
Investigation
- Collect and identify the information
- Case filing and assign investigation
- Review and analysis of claims
-
Resolution
- Email a report result
- corrective action and Rewards
- Penalties order and Issue Resolution